moxifloxacin has been researched along with Diabetic Feet in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arvis, P; Bogner, JR; Esguerra-Alcalen, M; Heldner, S; Kutaiman, A | 1 |
| Goriunov, SV; Prividentsev, AI; Stupin, VA; Vasin, VI; Zhilina, SV | 1 |
| Haak, T; Kees, F; Kees, MG; Kloft, C; Wicha, SG; Zink, K | 1 |
| Czaika, V; Drewelow, B; Gussmann, A; Klar, E; Koch, H; Kujath, P; Lobmann, R; Luebbert, C; Majcher-Peszynska, J; Mundkowski, RG; Ruf, BR; Sass, M; Schareck, W; Schipper, S | 1 |
| Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, NC | 1 |
| Cambria, RA; Edmiston, CE; Krepel, CJ; Nakeeb, A; Seabrook, GR; Somberg, LR; Towne, JB | 1 |
| Choudhri, S; Giordano, P; Lipsky, BA; Song, J | 1 |
4 trial(s) available for moxifloxacin and Diabetic Feet
| Article | Year |
|---|---|
[Vasin new fluoroquinolones in treatment of patients with infectious lesions in diabetic foot syndrome].
Topics: Anti-Bacterial Agents; Combined Modality Therapy; Diabetic Foot; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Severity of Illness Index; Staphylococcal Infections; Staphylococcus aureus; Surgical Procedures, Operative; Treatment Outcome | 2014 |
Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Foot; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines | 2011 |
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Diabetic Foot; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam; Treatment Outcome | 2013 |
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Databases, Factual; Diabetic Foot; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam | 2007 |
3 other study(ies) available for moxifloxacin and Diabetic Feet
| Article | Year |
|---|---|
Moxifloxacin in complicated skin and skin structure infections (cSSSIs): A prospective, international, non-interventional, observational study.
Topics: Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bites and Stings; Cellulitis; Cohort Studies; Debridement; Diabetic Foot; Drainage; Erysipelas; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Skin Diseases, Bacterial; Skin Ulcer; Surgical Wound Infection; Treatment Outcome; Young Adult | 2013 |
Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Diabetes Mellitus; Diabetic Foot; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Middle Aged; Monte Carlo Method; Moxifloxacin | 2015 |
In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.
Topics: Abdomen; Anti-Infective Agents; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Diabetic Foot; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2004 |